Extended Data Figure 1. Concentration of remdesivir prodrug and metabolites measured in serum and lung homogenates of rhesus macaques infected with SARS-CoV-2.

Two groups of six rhesus macaques were inoculated with SARS-CoV-2 strain nCoV-WA1-2020. Twelve hours post inoculation, one group was administered 10mg/kg intravenous remdesivir and the other group was treated with an equal volume of vehicle solution (2ml/kg). Treatment was continued 12hrs after the first treatment, and every 24 hrs thereafter with a dose of 5 mg/kg remdesivir or equal volume of vehicle solution (1ml/kg). (a) Serum concentration of remdesivir prodrug GS-5734, the dephosphorylated nucleoside product GS-441524 and the intermediate alanine metabolite GS-704277 over time as measured in by LCMS for all animals (n=12) in the study. Mean and standard deviation are shown. (b) Concentration of GS-441524 homogenized lung tissue collected from all six lung lobes from each animal (n=12) on 7 dpi, 24 hrs after the last remdesivir treatment was administered. Each dot represents the concentration of GS-441524 in one lung lobe. The center bar represents the median.